Achieve new breakthroughs in RNA with the Benchling R&D Cloud

This application note highlights the critical needs and complexities of RNA therapeutics R&D, and how Benchling has helped address these challenges for leading biopharma companies.


Because RNA therapeutics can target conditions that small molecules and proteins cannot address, researchers are now on the verge of treating previously "undruggable" diseases. From the approval of the first antisense oligonucleotide, aptamer, and siRNA, to the now famous launch of mRNA-based COVID-19 vaccines, the pipeline of RNA therapies and vaccines has expanded dramatically. However, as RNA therapeutics have gained traction scientifically and clinically, the software tools to engineer them have been frustratingly limited.

This application note highlights complexities in RNA therapeutics R&D as well as how Benchling can help overcome these hurdles.

Download application note

Join over 200,000 scientists using Benchling to power their biotech R&D

Helix Image